Enlivex
Develops Allocetra for knee osteoarthritis and manages a RAIN-centered digital-asset treasury.
Something off on this page? Send us feedback.
Profile
Develops Allocetra for knee osteoarthritis while holding and managing a RAIN-centered digital-asset treasury. With no saleable products or product-sales revenue, its clinical business depends on regulatory approval and future commercialization, while treasury results depend largely on RAIN fair-value movements.
Develops Allocetra, an off-the-shelf apoptotic-cell therapy designed to reprogram macrophages toward homeostasis. Clinical Operations focus almost exclusively on intra-articular treatment for age-related symptomatic knee osteoarthritis, with a randomized trial underway in the United States and European Union. The Israel-based team must generate adequate safety, pain, function, and durability evidence before the candidate can be commercialized.
Manages a digital-asset treasury centered on RAIN, the governance and utility token for a decentralized prediction- and options-markets protocol. Treasury Operations hold and manage RAIN and related instruments; their financial outcomes depend principally on fair-value movements rather than customer fees. Allocetra has no marketing approval, and RAIN is the primary treasury reserve asset.
Company facts
Key statistics
Year to date −87.9% · Average volume (30d) 378.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Nov 24, 2025 | D. Boral Capital | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Mar 30, 2026Q4 FY25 | −$0.45 | −$3.45 | −666.7% | — | — | — | +3.33% |
| Mar 25, 2026Q4 FY25 | −$1.29 | $410.25 | +31,791.8% | — | — | — | −9.17% |
| Dec 5, 2025Q3 FY25 | −$1.80 | −$0.12 | +93.5% | — | — | — | −9.09% |
| Nov 14, 2025Q3 FY25 | −$0.12 | −$0.09 | +25.0% | — | — | — | −1.61% |
Financial highlights
| 12 quarters | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$161.0K | −$36.0K | −$90.0K | −$85.0K | −$81.0K | −$76.0K | |
| Operating income | −$3.1M | −$5.6M | −$3.5M | −$3.1M | −$2.6M | −$5.9M | |
| Net income | −$2.6M | −$5.2M | −$3.5M | −$1.9M | −$2.2M | $1.24B | |
| Diluted EPS | −$1.80 | −$3.60 | −$2.40 | −$1.17 | −$1.38 | $386.85 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Dec 31, 2025Cash & short-term investments $5.9M · Total debt $641.0K · Total assets $2.33B · Shareholders' equity $1.93B
Dividends
No dividends on record.
Ownership
Shares outstanding 16.83M · Float 16.75M · 99.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Lind Global Asset Management XIV, LLC | 1.93M | 9.99% | 13G | Aug 13, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Anika Therapeutics
Marketed hyaluronic-acid injections for knee-OA pain.
- Pacira BioSciences
Marketed extended-release injection for knee-OA pain.
- P.A.R. Technology
Phase III injectable contender for knee-OA pain.
- Zimmer Biomet
Knee-replacement systems offer the procedural endpoint.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Enlivex | $1.36 | −0.47% | $22.7M | 0.0 | — | — | — |
| Anika Therapeutics | $21.10 | −0.50% | $282.4M | — | 34.5 | 2.3 | +15.6% |
| Pacira BioSciences | $25.76 | 0.00% | $1.01B | 73.3 | 8.3 | 1.4 | +6.2% |
| P.A.R. Technology | $19.15 | −0.05% | $789.9M | — | 17.2 | 1.6 | +18.7% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Median | 48.9 | 14.3 | 1.9 | +10.9% |